FDA Action Alert: Merck, BMS, Sarepta and More 6/17/2024

Opinion: Regulatory Flexibility Can Accelerate Rare Disease Drug Development 6/17/2024

Immune system cells called macrophages play an unexpected role in the complicated connection between obesity and cancer, a Vanderbilt University Medical Center-led research team has discovered.

Obesity increases the frequency of macrophages in tumors and induces their expression of the immune checkpoint protein PD-1 - a target of cancer immunotherapies. The findings, published June 12 in the journal Nature, provide a mechanistic explanation for how obesity can contribute to both increased cancer risk and enhanced responses to immunotherapy.

Telix Abandons IPO Plans at Last Minute, Cites ‘Current Market Conditions’ 6/14/2024

J.P. Morgan Raises Over $500M for First Biotech Venture Capital Fund 6/14/2024

SCOTUS Upholds Access to Abortion Pill, Pharma Industry Applauds Court’s Ruling 6/14/2024

GLP-1 Global Obesity Market to Reach $111B by 2033, Despite Headwinds: GlobalData 6/14/2024

With Donanemab on the Cusp of Approval, Proper Alzheimer’s Diagnosis Is Urgent 6/14/2024

BMS’ Augtyro Wins FDA Accelerated Approval for NTRK-Positive Solid Tumors 6/14/2024

EU Says India’s Alchem Is Part of International Drug Price-Fixing Cartel 6/14/2024

Proteins are workhorses that carry out most of the biological functions in our cells. While the genes we inherit from our parents, our so-called genome, are fixed and usually remain unchanged throughout our lives, proteins in our bodies are constantly changing, as we age, under different health conditions and upon stimulation, such as with medical treatment.

This makes monitoring proteins and their molecular changes - the study of proteomics - beneficial for drug discovery, disease diagnosis and health management.

Secondary Cancer Risk Is Low After CAR T Cell Treatment: Stanford Study 6/13/2024

Moderna’s Next-Gen COVID Vaccine Beats Current Shot in Pivotal Adult Efficacy Trial 6/13/2024

Pfizer’s Gene Therapy for Duchenne Muscular Dystrophy Fails Phase III Trial 6/13/2024

Santa Ana Bio Launches With $168M, Targets Autoimmune and Inflammatory Diseases 6/13/2024

Foresite Raises $900M in Sixth Fund to Invest in Life Science Startups 6/13/2024

Massachusetts’ Life Sciences Job Growth Slows, but 10-Year Outlook Remains Strong: Report 6/13/2024

Coherus, Junshi’s PD-1 Blocker Loqtorzi Aces Phase III Liver Cancer Trial 6/13/2024

Career Coach: How to Navigate 2 Job Interviews at the Same Company 6/13/2024

Drugs with the potential to change the course of Alzheimer’s disease are expected to be approved by mid-year in the UK. Healthcare services may need to change to ensure that all patients have equitable access to these new modifying anti-amyloid therapies, according to research led by Queen Mary University of London and University College London (UCL).

Alzheimer's disease is the most common cause of dementia. Of the 944,000 people living with dementia in the UK, 60-80% have Alzheimer's.